
FDA Clears NeuroStar TMS Therapy for Adolescents with Depression, A First in the Field
MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) has announced that the U.S. Food and Drug Administration (FDA) has cleared NeuroStar TMS (transcranial magnetic stimulation) for use as a first-line add-on …
FDA Clears NeuroStar TMS Therapy for Adolescents with Depression, A First in the Field Read More